$TMP

Tompkins: Fourth Quarter Earnings Overview

Tompkins Financial Corp. announced strong financial results for its fourth quarter, reporting a net profit of $96.2 million and earnings of $6.70 per share. After excluding one-time gains, adjusted earnings were $1.78 per share, with total revenue reaching $226.7 million and net revenue exceeding analysts' expectations at $194.8 million. For the full year, the company achieved a total profit of $161.1 million ($11.24 per share) and annual revenue of $446.6 million.

Original reporting
Bitget · 101 finance
Published Jan 30, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 30, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tompkins: Fourth Quarter Earnings Overview — source image
Decision brief

The 30-second read

$TMPBullishHigh
01

Why it matters

The strong quarterly results reinforce the company's market position and could attract investor interest.

02

Market read

The earnings report is highly relevant for investors in regional banks and financial sector traders.

03

What to watch

Potential macroeconomic headwinds or interest rate changes could offset positive earnings impact.

Relevance 6/10Timing: Immediate, as earnings reports influence short-term trading decisions.

Background

Tompkins Financial Corp. is a regional bank with a focus on community banking services.

Company-level read

Ticker impact

$TMPBullishHigh confidence
Context

The company's strong quarterly earnings and revenue surpassing analyst expectations suggest positive momentum.

Expected impact

Moderate upward movement in stock price over the next 1-3 weeks.

Evidence & confidence

Strong earnings, revenue beats, and positive analyst expectations typically drive short-term stock price increases.

Market effects

The positive earnings report may boost confidence in the regional banking sector.

Potential uplift in regional financial stocks.

Limited, as the news pertains to a regional financial institution.

Counterpoint

The earnings may already be priced in, and any subsequent profit-taking could lead to a short-term pullback.

Key entities

  • Tompkins Financial Corp.

    A regional financial services company.

Related articles

$TMPHigh

Tompkins Financial Corporation Reports Financial Results for Third Quarter of 2026

TOMPKINS FINANCIAL CORP (TMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. For more information contact: Stephen S. Romaine, President & CEO Matthew Tomazin, Executive VP & CFO Tompkins Financial Corporation ( 888) 503-5753 For Immediate Release Friday, October 23, 2026 Tompkins Financial Corporation Reports Financial Results for Third Quarter of 2026 I

$TMPMed

Tompkins Financial Corporation (TMP) Q3 EPS $2.00, Up 21% YoY

Tompkins Financial Corporation reported Q3 2026 diluted EPS of $2.00, up 21% YoY and down 2% QoQ, with net interest margin at 3.65% and net interest income up 21% YoY to $77.3M. The company attributes these results to improving core banking metrics post-2025 divestiture, with NIM and loan growth driving EPS.

$TMPMed

Tompkins Financial Corporation Reports Record Financial Results for Third Consecutive Quarter

TOMPKINS FINANCIAL CORP (TMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pressrelease.htm EX-99.1 Document For more information contact: Stephen S. Romaine, President & CEO Matthew Tomazin, Executive VP & CFO Tompkins Financial Corporation ( 888) 503-5753 For Immediate Release Friday, July 24, 2026 Tompkins Financial Corporation Report

$BMYMed

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.